'On consolidated basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of Gland Pharma has increased 22.49% to Rs 1695.36 crore. Operating profit margin has declined from 26.01% to 25.65%, leading to 20.82% rise in operating profit to Rs 434.89 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 32.14% to 32.11%. Purchase of finished goods cost fell from 0.16% to 0.09%. Employee cost increased from 25.19% to 25.71%. Other expenses fell from 16.06% to 15.73%. Power and Oil fuel cost fell from 4.02% to 3.27%.
Other income rose 8% to Rs 63.17 crore. PBIDT rose 19.02% to Rs 498.06 crore. Provision for interest fell 82.78% to Rs 3.93 crore.
PBDT rose 24.90% to Rs 494.13 crore. Provision for depreciation rose 11.75% to Rs 10...
Pleaselogin & subscribe to view the full report.
More Reports
|
|